Answers are grounded in this paper and cite their sources.
OWise Breast Cancer is a digital tool for supported self-management in people affected by breast cancer. This study reports the findings from the ADAPT randomized controlled trial (RCT), concerning the impact of OWise on patient activation (Patient Activation Measure, PAM-13) as the primary outcome, with health-related quality of life (HRQoL, European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire, EORTC QLQ-C30), and health status (EuroQol 5-Dimension 5-Level questionnaire, EQ-5D-5L) as secondary outcomes. Women with early-stage breast cancer were randomly assigned to standard care (control) or standard care in addition to OWise (intervention). Data were collected using a demographic questionnaire, the PAM-13, the EORTC QLQ-C30, and the EQ-5D-5L at baseline, six weeks, three months, six months, and one year from diagnosis. Linear mixed effect model regression was used to assess the effect of OWise over the first year from diagnosis while correcting for intra-participant correlation. A total of 166 participants were included, with 85 being randomized into the intervention. No significant differences (p>0.05) in the PAM13 scores, EORTC QLQ-C30 (global QoL, physical functioning, emotional functioning, pain, and fatigue), and EQ-5D-5L index between the control and intervention group were observed over time. It is important to note that there was significant non-adherence to using OWise among the intervention group. OWise had no statistically significant impact on patient activation, HRQoL, and health status over time compared to standard care alone. Future research should focus on identifying and addressing barriers to digital tool engagement to improve efficacy.
No takes yet. Share an insight, caveat, or question.
Peeters et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: